Prostate Cancer UK ‘disappointed’ at suspension of NICE abiraterone appraisal

Prostate Cancer UK 'disappointed' at suspension of NICE abiraterone appraisal

Today the National Institute for Health and Clinical Excellence (NICE) has announced it has suspended its appraisal of abiraterone for men with incurable prostate cancer who have not yet had chemotherapy.

Commenting on the development Owen Sharp, Chief Executive at Prostate Cancer UK, said:

"It is extremely disappointing that - due to delays from the manufacturer - NICE has been forced to push back its appraisal of abiraterone for men with incurable prostate cancer who have not yet had chemotherapy. The news will come as a huge blow to those men in the final stages of the disease who had hoped for the chance to delay chemotherapy and the debilitating side effects that can come with it.

"Although doctors can still prescribe abiraterone prior to chemotherapy, its costs may not be covered by local NHS providers. For this we urgently needed NICE - and its Scottish and Northern Irish equivalents - to appraise the drug and we'd hope that they'd recommend it for routine use on the NHS.

"We implore the drug manufacturer and the UK's drug appraisal bodies to find a way forward as a matter of urgency. There are thousands of men with prostate cancer who have no time to waste."

    comments powered by Disqus